홈 > 시장보고서 > 의약품

시장보고서

상품코드

1790281

날트렉손 및 부프레노르핀 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 투여 경로별, 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product (Naltrexone, Buprenorphine), By Route Of Administration, By Application, By Distribution Channel (Hospitals Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

나트렉손과 부프레노르핀 시장 개요

세계 나트렉손과 부프레노르핀 시장 규모는 2024년에 41억 7,000만 달러로 평가되었습니다. 2033년에는 98억 달러에 달하고, 2025-2033년 9.25%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장은 약물 사용 장애의 유병률 증가와 오피오이드 사용 장애 치료에 대한 인식이 높아짐에 따라 성장할 것으로 예측됩니다. 정부의 이니셔티브으로 첨단 중독 치료 솔루션에 대한 접근성이 더욱 향상되고 있습니다.

WHO, 오피오이드 치료 가이드라인을 업데이트했습니다.

2025년 2월, 세계보건기구(WHO)는 효과적인 개입에 대한 접근성을 확대하기 위해 오피오이드 중독 치료 및 과다복용 예방에 대한 가이드라인을 업데이트했습니다. 개정된 가이드라인에서는 오피오이드 의존에 대한 가장 효과적인 치료법으로 메트돈 또는 부프레노르핀을 이용한 오피오이드 작용제 유지요법(OAMT)의 중요성을 강조했습니다. WHO는 특히 지역사회에서 과다 복용으로 인한 사망을 예방하기 위해 나록손을 더 널리 사용할 수 있도록 권장했습니다. 새로운 지침은 규제 장벽을 낮추고 약물 피해 경감 서비스에 대한 투자를 늘리도록 요구했습니다. 또한, 의료 서비스 제공업체에게 증거 기반, 환자 중심, 차등 없는 치료를 제공할 것을 요구했습니다. 이 권고안은 증가하는 오피오이드 관련 건강 문제를 해결하고 전 세계적으로 공중보건 성과를 개선하기 위해 각국을 지원하는 것을 목표로 하고 있습니다.

지역별 시장 점유율 분석, 2024년과 2033년
지역별 시장 대시보드
시장 규모와 예측 동향 분석, 2021-2033년
북미
- 국가별, 2021-2033년
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

참가자 개요
기업 시장 현황 분석
기업 분류
전략 매핑
기업 개요/상장기업
- Indivior PLC
- Collegium Pharmaceutical(BioDelivery Sciences International, Inc.)
- Alkermes, Inc.
- Orexo US, Inc.(a part of Orexo AB)
- Titan Pharmaceuticals, Inc.
- Omeros Corporation
- Camurus
- Sun Pharmaceutical Industries Ltd

LSH 25.08.25

Naltrexone And Buprenorphine Market Summary

The global naltrexone and buprenorphine market size was estimated at USD 4.17 billion in 2024 and is projected to reach USD 9.80 billion by 2033, growing at a CAGR of 9.25% from 2025 to 2033. The market is expected to grow due to the increasing prevalence of substance use disorders and greater awareness of opioid use disorder treatments. Government initiatives are further increasing access to advanced addiction care solutions.

WHO Updates Opioid Treatment Guidelines

In February 2025, The World Health Organization (WHO) updated its guidelines on opioid dependence treatment and overdose prevention to expand access to effective interventions. The revised guidelines emphasized the importance of using opioid agonist maintenance treatment (OAMT) with methadone or buprenorphine as the most effective therapy for opioid dependence. WHO also recommended making naloxone more widely available to prevent overdose-related deaths, especially in community settings. The new guidance called for reducing regulatory barriers and increasing investment in harm-reduction services. Additionally, the update urged healthcare providers to deliver evidence-based, person-centered, and non-discriminatory care. These recommendations were aimed at supporting countries in addressing rising opioid-related health challenges and enhancing public health outcomes globally.

Global Naltrexone And Buprenorphine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Naltrexone
Buprenorphine
- BELBUCA
- Sublocade
- Suboxone
- Zubsolv
- Others
Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
Naltrexone
- Oral Administration
- Injectable Administration
- Implantable Administration
Buprenorphine
- Oral Administration
- Injectable Administration
- Implantable Administration
Application Outlook (Revenue, USD Million, 2021 - 2033)
Naltrexone
- Opioid use disorder (OUD)
- Alcohol use disorder (AUD
Buprenorphine
- Opioid use disorder (OUD)
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals Pharmacies
Retail Pharmacies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Route of Administration
- 1.2.3. Application
- 1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

Chapter 4. Naltrexone and Buprenorphine Market: Product Business Analysis

4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Naltrexone
- 4.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
4.5. Buprenorphine
- 4.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
- 4.5.2. BELBUCA
  - 4.5.2.1. BELBUCA Market, 2021 - 2033 (USD Million)
- 4.5.3. Sublocade
  - 4.5.3.1. Sublocade Market, 2021 - 2033 (USD Million)
- 4.5.4. Suboxone
  - 4.5.4.1. Suboxone Market, 2021 - 2033 (USD Million)
- 4.5.5. Zubsolv
  - 4.5.5.1. Zubsolv Market, 2021 - 2033 (USD Million)
- 4.5.6. Others
  - 4.5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Naltrexone and Buprenorphine Market: Route of Administration Business Analysis

5.1. Route of Administration Market Share, 2024 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
5.4. Naltrexone
- 5.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
- 5.4.2. Oral Administration
  - 5.4.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
- 5.4.3. Injectable Administration
  - 5.4.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
- 5.4.4. Implantable Administration
  - 5.4.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
5.5. Buprenorphine
- 5.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
- 5.5.2. Oral Administration
  - 5.5.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
- 5.5.3. Injectable Administration
  - 5.5.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
- 5.5.4. Implantable Administration
  - 5.5.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)

Chapter 6. Naltrexone and Buprenorphine Market: Application Business Analysis

6.1. Application Market Share, 2024 & 2033
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Naltrexone
- 6.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
- 6.4.2. Opioid use disorder (OUD)
  - 6.4.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
- 6.4.3. Alcohol use disorder (AUD)
  - 6.4.3.1. Alcohol use disorder (AUD) Market, 2021 - 2033 (USD Million)
6.5. Buprenorphine
- 6.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
- 6.5.2. Opioid use disorder (OUD)
  - 6.5.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)

Chapter 7. Naltrexone and Buprenorphine Market: Distribution Channel Business Analysis

7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. End Use Disease Prevalence
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Framework
  - 8.4.2.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. End Use Disease Prevalence
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Framework
  - 8.4.3.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. End Use Disease Prevalence
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Framework
  - 8.4.4.5. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
- 8.5.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. End Use Disease Prevalence
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Framework
  - 8.5.2.5. Uk Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. End Use Disease Prevalence
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Framework
  - 8.5.3.5. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. End Use Disease Prevalence
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. Reimbursement Framework
  - 8.5.4.5. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. End Use Disease Prevalence
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Reimbursement Framework
  - 8.5.5.5. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. End Use Disease Prevalence
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Reimbursement Framework
  - 8.5.6.5. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. End Use Disease Prevalence
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Reimbursement Framework
  - 8.5.7.5. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. End Use Disease Prevalence
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Reimbursement Framework
  - 8.5.8.5. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. End Use Disease Prevalence
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Reimbursement Framework
  - 8.5.9.5. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. End Use Disease Prevalence
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Framework
  - 8.6.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. End Use Disease Prevalence
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Framework
  - 8.6.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. End Use Disease Prevalence
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Framework
  - 8.6.4.5. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. End Use Disease Prevalence
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Framework
  - 8.6.5.5. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. End Use Disease Prevalence
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. Reimbursement Framework
  - 8.6.6.5. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. End Use Disease Prevalence
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Reimbursement Framework
  - 8.6.7.5. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. End Use Disease Prevalence
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Reimbursement Framework
  - 8.7.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. End Use Disease Prevalence
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Reimbursement Framework
  - 8.7.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. End Use Disease Prevalence
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. Reimbursement Framework
  - 8.8.2.5. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. End Use Disease Prevalence
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Reimbursement Framework
  - 8.8.3.5. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. End Use Disease Prevalence
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. Reimbursement Framework
  - 8.8.4.5. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. End Use Disease Prevalence
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Reimbursement Framework
  - 8.8.5.5. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. Indivior PLC
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. Alkermes, Inc.
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. Orexo US, Inc. (a part of Orexo AB)
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. Titan Pharmaceuticals, Inc.
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. Omeros Corporation
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. Camurus
  - 9.5.7.1. Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. Sun Pharmaceutical Industries Ltd
  - 9.5.8.1. Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Strategic Initiatives

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 5,950

￦ 8,649,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 6,950

￦ 10,103,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 8,950

￦ 13,010,000

※ 부가세 별도

날트렉손 및 부프레노르핀 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 투여 경로별, 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product (Naltrexone, Buprenorphine), By Route Of Administration, By Application, By Distribution Channel (Hospitals Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 날트렉손 및 부프레노르핀 시장 변수, 동향, 범위

제4장 날트렉손 및 부프레노르핀 시장 : 제품 비즈니스 분석

제5장 날트렉손 및 부프레노르핀 시장 : 투여 경로 비즈니스 분석

제6장 날트렉손 및 부프레노르핀 시장 : 용도 비즈니스 분석

제7장 날트렉손 및 부프레노르핀 시장 : 유통 채널 비즈니스 분석

제8장 날트렉손 및 부프레노르핀 시장 : 지역별, 추정·동향 분석